TGFB1 and ovarian carcinoma: Activation of SMAD2/3 signaling is a known downstream effect of TGF-β signaling, and we observed enrichment of the SMAD2/3 signaling pathway in CD105-high ovarian cancer cell lines and tumors (Figure 2).